<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988169</url>
  </required_header>
  <id_info>
    <org_study_id>09-026</org_study_id>
    <nct_id>NCT00988169</nct_id>
  </id_info>
  <brief_title>Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations</brief_title>
  <official_title>A Phase II Trial of Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Activating Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ascenta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      Advanced stage lung cancer is generally treated with anti-cancer medication called
      chemotherapy. Most lung cancer is caused by cigarette smoking. However, some lung cancers
      develop in people who never smoked or who only smoked for a short period of time. This type
      of lung cancer may respond to a medication called erlotinib (Tarceva). Erlotinib is an
      anticancer pill that is approved by the Food and Drug Administration (FDA) for use in
      patients with advanced lung cancer. Unfortunately, erlotinib does not work for all patients
      or only works for a period of time. The doctors are trying to find ways to improve the effect
      of erlotinib by combining it with another anti-cancer medication.

      Ascenta Therapeutics, Inc. has developed a drug called AT-101 as a potential treatment for
      cancer. AT-101 is an investigational drug. That means that AT-101 is not approved by the
      United States Food and Drug Administration (FDA) for general use. The FDA does permit its use
      in studies like this one to determine whether it is safe and effective.

      This is the first study to examine the effects of AT-101 and erlotinib. It is hoped that by
      combining AT-101 with erlotinib, AT-101 may help erlotinib work better to shrink lung cancer.
      Studies that have been performed in the laboratory suggest that AT-101 in combination with
      erlotinib may be more effective at shrinking tumors than erlotinib alone.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Objective Response Rate</measure>
    <time_frame>21 days after cycle one</time_frame>
    <description>(CR+PR, by WHO Criteria for Standard Bidimensional Tumor Measurement) After One 21-day Cycle of Combination Therapy With Erlotinib and AT-101</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>oral erlotinib and pulsed doses of oral AT-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This will be an open-label, single institution, phase II trial. The study will assess the efficacy of the combination of the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and the novel pan-Bcl-2 inhibitor, AT-101, in treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations A planned pause of 21 days will be performed after enrollment of the 10th and 20th patient to assess for excessive toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral erlotinib and pulsed doses of oral AT-101</intervention_name>
    <description>Patients will receive oral erlotinib 100 mg daily and pulsed doses of oral AT-101 given 40 mg twice daily on days 1-3 of a 21-day cycle. If the initial combination of erlotinib and AT-101 is tolerated, dose escalation of erlotinib to 150 mg daily will be allowed at the discretion of the treating investigator at the start of cycle 2. Patients will continue receiving treatment on study until they refuse further therapy, develop evidence of progressive disease, or develop unacceptable toxicity or a medical condition that would, in the judgment of the investigator,</description>
    <arm_group_label>oral erlotinib and pulsed doses of oral AT-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and the willingness to sign a written informed consent form; the
             consent form must be signed by the patient prior to any study-specific procedures.

          -  Patients age ≥ 18 years with histologically confirmed wet Stage IIIB (with malignant
             pleural effusion) or Stage IV non-small cell lung cancer (metastatic or recurrent).

          -  Pathologic confirmation of non-small cell lung cancer at Memorial Sloan-Kettering
             Cancer Center.

          -  Presence of exon 19 or exon 21 EGFR activating mutation.

          -  No prior EGFR tyrosine kinase therapy.

          -  No prior systemic therapy for advanced NSCLC (Stage IIIB with malignant effusion or
             Stage IV)

          -  Karnofsky performance status &gt; or = to 70% OR ECOG performance status ≤ 2.

          -  Measurable disease defined as greater than or equal to one known/suspected malignant
             lesion &gt; or = to 1 cm measurable in two dimensions.

          -  Adequate hematologic, renal, and/or hepatic function: WBC &gt; or = to 3,000/ul,
             hemoglobin &gt; or = to 9.0 g/dl, platelet count &gt; or = to 100,000/ul, total bilirubin ≤
             1.5 X UNL, AST ≤ 2.5 X UNL, and serum creatinine within 1.5 x the upper limit of
             normal (&lt;1.95 at MSKCC) or calculated creatinine clearance &gt; or = to 60 ml/min.

          -  Able to swallow and retain oral medication.

          -  Willingness and ability to comply with study procedures and follow-up examination.

          -  Four weeks since any major surgery, completion of radiation, or completion of all
             prior chemotherapy.

          -  Acute toxicities of any prior therapy must have resolved to &lt; Grade 1 or baseline
             prior to starting study therapy.

          -  Effective contraception.

        Exclusion Criteria:

          -  Prior treatment with gefitinib, erlotinib, or other EGFR tyrosine kinase inhibitor
             therapy.

          -  Concurrent cytotoxic or biological therapy.

          -  Known KRAS mutation.

          -  History within the past 6 months of myocardial infarction, cardiac stent placement, or
             intermittent ischemia with troponin leak.

          -  Active secondary malignancy or history of other malignancy within the last 3 years
             except non-melanoma skin cancer and in-situ carcinoma of the cervix.

          -  Active, serious comorbid medical conditions including severe infection, malnutrition,
             unstable angina, congestive heart failure (New York Heart Association Class III or
             IV), pulmonary fibrosis, or condition that would be felt by treating physician to
             preclude safe participation in the clinical trial.

          -  Patients with malabsorption syndrome or diseases significantly affecting the
             gastrointestinal tract including prior gastric resection or small bowel resection,
             inflammatory bowel disease, or partial or complete small bowel obstruction.

          -  Unstable brain or leptomeningeal metastases including patients who continue to require
             glucocorticoids for brain or leptomeningeal metastases.

          -  Women who are pregnant or breast-feeding.

          -  Inability/unwillingness to comply with protocol treatment or follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naiyer Rizvi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>October 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2009</study_first_posted>
  <results_first_submitted>October 19, 2015</results_first_submitted>
  <results_first_submitted_qc>October 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2015</results_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AT-101</keyword>
  <keyword>erlotinib</keyword>
  <keyword>Unresectable Stage IIIB</keyword>
  <keyword>09-026</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gossypol acetic acid</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Gossypol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Erlotinib and Pulsed Doses of Oral AT-101</title>
          <description>Treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Erlotinib and Pulsed Doses of Oral AT-101</title>
          <description>Treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Radiographic Objective Response Rate</title>
        <description>(CR+PR, by WHO Criteria for Standard Bidimensional Tumor Measurement) After One 21-day Cycle of Combination Therapy With Erlotinib and AT-101</description>
        <time_frame>21 days after cycle one</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Erlotinib and Pulsed Doses of Oral AT-101</title>
            <description>Treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Objective Response Rate</title>
          <description>(CR+PR, by WHO Criteria for Standard Bidimensional Tumor Measurement) After One 21-day Cycle of Combination Therapy With Erlotinib and AT-101</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Minor Response (MR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Erlotinib and Pulsed Doses of Oral AT-101</title>
          <description>Treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Kris</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4205</phone>
      <email>krism@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

